IGF-1 LR3

IGF-1 LR3 dramatically increases glucose uptake in muscle tissue, lowering blood glucose. Symptoms include tremor, sweating, dizziness, confusion, and rapid heartbeat. Manage by consuming fast-acting carbohydrates (glucose tablets, juice, honey) immediately. Always have carbs available during and after injection. Avoid fasting during the first 2-4 hours post-injection. Monitor blood glucose if diabetic or pre-diabetic.

IGF-1 LR3 stimulates rapid tissue growth, including connective tissue, which can cause joint discomfort, particularly in the knees, shoulders, and wrists. This is typically self-resolving and mild. Manage with rest, ice, and NSAIDs if needed. Ensure adequate hydration and electrolyte intake. Symptoms usually resolve within days of discontinuation.

Rapid growth of connective tissue in the wrist can compress the median nerve, causing numbness, tingling, or pain in the hand. This is more common with prolonged use beyond 4 weeks. Manage by wearing a wrist splint at night, reducing injection frequency, or discontinuing use. Symptoms typically resolve within 1-2 weeks of stopping the peptide.

Repeated injections at the same site cause localized fat loss (lipoatrophy) or, less commonly, fat gain (lipohypertrophy). This is cosmetic and reversible. Prevent by strictly rotating injection sites with each dose, maintaining at least 1-1.5 inches between injection points, and avoiding the same site more than once per week. Affected areas typically normalize within 3-6 months of proper rotation.

Local inflammation, erythema, or pruritus at the injection site can occur due to the peptide itself or improper injection technique. Manage by ensuring proper site rotation, using sterile technique, and allowing the solution to reach room temperature before injection. Apply ice if swelling occurs. Reactions typically resolve within 24 hours.

Mild to moderate headaches have been reported, possibly related to rapid metabolic changes or hypoglycemia. Manage by ensuring adequate carbohydrate intake post-injection and staying well-hydrated. Headaches typically resolve within hours.

Mild nausea can occur, particularly if injected on an empty stomach or if hypoglycemia develops. Manage by eating a small meal 30-60 minutes before injection and consuming carbohydrates post-injection. Nausea is typically transient.

Mild peripheral edema or water retention can occur due to increased protein synthesis and metabolic activity. Manage by maintaining adequate hydration and electrolyte balance. Edema typically resolves within days of discontinuation.

Prolonged IGF-1 LR3 use beyond 4 weeks can cause acromegaly-like changes including jaw enlargement, hand/foot growth, and facial coarsening. These changes are largely irreversible. Strictly adhere to the 4-week maximum cycle length. Discontinue immediately if any signs of acromegaly develop.

Chronic IGF-1 elevation can stimulate growth of internal organs (heart, liver, kidneys) and increase cancer risk. This is a theoretical concern with prolonged use. Limit use to 4-week cycles with extended breaks (at least 4-8 weeks) between cycles. Do not exceed recommended dosages or cycle duration.

Anaphylaxis or severe allergic reactions are rare but possible. Symptoms include difficulty breathing, throat tightness, severe rash, or swelling of face/lips. Seek emergency medical attention immediately if these occur. Have an epinephrine auto-injector available if you have a history of peptide allergies.